Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement

Gianfranco Ferraccioli

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Suppression of the immunoinflammatory cascade by targeting interleukin 6 (IL-6) mediated effects constitutes a therapeutic option for chronic inflammatory diseases. Tocilizumab is the only IL-6 inhibitor (IL-6i) licensed for rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA), but also other agents targeting either IL-6 or its receptor are investigated in various indications.
Original languageEnglish
Pages (from-to)583-589
Number of pages7
JournalEARD
Volume72
DOIs
Publication statusPublished - 2013
Externally publishedYes

Keywords

  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • Arthritis, Juvenile
  • Arthritis, Rheumatoid
  • Consensus
  • Humans
  • Interleukin-6
  • Spondylitis, Ankylosing

Fingerprint

Dive into the research topics of 'Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement'. Together they form a unique fingerprint.

Cite this